UPDATE: RBC Capital Starts Xenon Pharmaceuticals (XENE) at Outperform

October 28, 2021 5:58 AM EDT
Get Alerts XENE Hot Sheet
Price: $27.70 +0.95%

Rating Summary:
    11 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 15 | New: 62
Trade Now! 
Join SI Premium – FREE
(Updated - October 28, 2021 5:58 AM EDT)

RBC Capital analyst Brian Abrahams initiates coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Outperform rating and a price target of $43.00.

The analyst comments "Initiating coverage of XENE with an Outperform, Speculative Risk rating and $43 price target. We believe strong ph.II data for lead drug '1101 in adult focal epilepsy and numerous properties that resonated well with our KOL consultants suggest a high likelihood of ph.III translatability, ultimate approval, and commercialsuccess – with earlier pipeline programs potentially providing additional out-year drivers. While recentshare upside now better reflects some of these prospects and there are fewer major NT clinical catalysts, we still see potential for further appreciation as the value of its portfolio becomes increasingly recognized."

For an analyst ratings summary and ratings history on Xenon Pharmaceuticals click here. For more ratings news on Xenon Pharmaceuticals click here.

Shares of Xenon Pharmaceuticals closed at $30.09 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

RBC Capital